Tackling cancer through real world data and AI
OPTIMA seeks to use artificial intelligence (AI) to improve care for patients with prostate, breast and lung cancer.OPTIMA’s goal is to design, develop and deliver the first interoperable, GDPR-compliant real-world oncology data and evidence generation platform in Europe, to potentially advance cancer treatments.
The public-private research program is part of the Innovative Medicines Initiative (IMI), which is promoted by the European Union (EU) and the European Federation of Pharmaceutical Companies and Associations (EFPIA).
OPTIMA’s vision is that every patient should have access to the most up-to-date individualised treatments and innovative therapies. By strengthening shared decision-making through dynamic computer-interpretable guidelines (CIGs), innovative access to broad data sets and AI-driven technology and tools, Optima wants to improve oncology care in Europe.
A Public Patient Advisory Group (PPAG) for OPTIMA has been established and aligned with the European Cancer Patient Coalition (ECPC). The group will provide feedback and suggestions from patients during all aspects of the project’s journey and help to disseminate the outcomes. Also, the PPAG will be involved in activities that impact communities of people living with lung, breast and prostate cancer and the creation of educational material.
Understanding real-world treatment outcomes of novel compounds outside of well controlled randomised controlled trials (RCTs) has become a vital component of drug development, regulatory approval, access to market, and post-market assessment for pharmaceutical companies and regulators. OPTIMA seeks to improve the availability of real-world oncology data.